RxDoctor Payments Data

Iradj Maany

Addiction Medicine · Phila, PANPI 1912005794

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 27.0% of the total. Reporting peaked in 2019 at $1,732 and has fallen 86.7% since, to $231 in 2024.

$2,571in general payments, 2019–2025

Across 66 payments — averaging $38.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$694
  • Otsuka America Pharmaceutical, Inc.$491
  • Johnson & Johnson$286
  • Takeda Pharmaceuticals U.S.A., Inc.$164
  • Lundbeck LLC$150
  • Sunovion Pharmaceuticals Inc.$147
  • plus $639 from 9 others

What the payments were for

  • Food & beverage$2,571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,571 in reported general payments places this provider in the 80th percentile of 82 addiction medicine providers in Pennsylvania.

See all addiction medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,380
Medicare patients
36
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Desvenlafaxine Succinate ErDesvenlafaxine Succinate30$4,451
Clozapine12$959
Buspirone Hcl34$943
Lorazepam57$744
Alprazolam87$592
Bupropion XlBupropion Hcl30$516
Divalproex Sodium17$441
Escitalopram Oxalate24$432
Oxcarbazepine23$428
Trazodone Hcl69$408
Duloxetine Hcl42$400
Estazolam16$374
Fluoxetine Hcl49$300
Divalproex Sodium ErDivalproex Sodium14$299
Gabapentin18$290

Paid to pharmacies, not to this prescriber.

Other addiction medicine in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →